Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Hep C Discussion Forum -> Hep C News -> motley fool
Post Info TOPIC: motley fool
Huey


Guru

Status: Offline
Posts: 678
Date:
motley fool
Permalink  
 

 

Recs

2

 

Should Gilead Sciences, inc. Fear This New Competitor Drug?

By Todd Campbell | More Articles | Save For Later
August 26, 2014 | Comments (0)

According to ViiV Healthcare -- GlaxoSmithKline (NYSE: GSK  ) , Pfizer (NYSE: PFE  ) , and Shionogi's HIV drug consortium -- one in three Americans fails to take their HIV medication as prescribed. That means hundreds of thousands of patients aren't receiving the medicine necessary to delay the progression of HIV and the onset of AIDS.

That creates a significant hurdle for policy makers eager to lower HIV incidence rates and drugmakers eager to boost prescription volume for next-generation therapies.

As a result, drugmakers are innovating HIV treatment by creating multi-drug, single-tablet therapies designed to make treatment regimens easier on patients.

Source: ViiV Healthcare.

The latest of these combination therapies to win FDA approval is ViiV's Triumeq, a medicine that consists of ViiV's recently approved Tivicay and two older drugs: abacavir and lamivudine.

ViiV hopes that this multi-drug combination can not only improve patient adherence rates, but win away market share from HIV drug treatment leader Gilea



__________________

  HCV Genotype 3a , now Psot-Tx was on S/riba. First VL was 5.8 mil on 7-5-13 then "und" at 3.8 weeks. 06/13/14 still und. off meds 3 days back on 7/29 Last pill 08/10/14 SVR+4

 
Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.
Hep C Discussion Forum -> Hep C News -> motley fool
Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.